$-0.01
(Market cap
$12 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
5.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-4.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.9
-
Face value
--
-
Shares outstanding
31,144,754
5 Years Aggregate
CFO
$-164.48 Mln
EBITDA
$-209.47 Mln
Net Profit
$-235.21 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Senti Biosciences Inc (SNTI)
| -68.1 | -10.3 | -66.0 | -77.0 | -63.3 | -68.0 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Senti Biosciences Inc (SNTI)
| -70.4 | -46.5 | -53.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Senti Biosciences Inc (SNTI)
|
0.3 | 11.7 | 0.1 | -49.6 | -91,136.4 | -- | -- | 5.5 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Senti Biosciences Inc (SNTI)
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates... utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California. Read more
-
Co-founder, CEO, President & Director
Dr. Timothy K. Lu M.D., Ph.D.
-
Co-founder, CEO, President & Director
Dr. Timothy K. Lu M.D., Ph.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Senti Biosciences Inc (SNTI)
What is the current share price of Senti Biosciences Inc (SNTI) Today?
The share price of Senti Biosciences Inc (SNTI) is $0.33 (NASDAQ) as of 04-Sep-2026 13:28 EDT. Senti Biosciences Inc (SNTI) has given a return of -63.34% in the last 3 years.
What is the current PB & PE ratio of Senti Biosciences Inc (SNTI)?
Since, TTM earnings of Senti Biosciences Inc (SNTI) is negative, P/E ratio is not available.
The P/B ratio of Senti Biosciences Inc (SNTI) is 5.45 times as on 28-Aug-2026, a 5 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.38 |
4.18 |
2024 |
-0.31 |
0.63 |
2023 |
-0.41 |
0.44 |
2022 |
-0.13 |
0.05 |
2021 |
-0.78 |
0.71 |
What is the 52 Week High and Low of Senti Biosciences Inc (SNTI)?
The 52-week high and low of Senti Biosciences Inc (SNTI) are Rs 2.88 and Rs 0.33 as of 05-Sep-2026.
What is the market cap of Senti Biosciences Inc (SNTI)?
Senti Biosciences Inc (SNTI) has a market capitalisation of $ 12 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Senti Biosciences Inc (SNTI)?
Before investing in Senti Biosciences Inc (SNTI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.